Curious Dr. George: In the cancer domain, PotentiaMetrics emphasizes real-world data layered onto the world’s academic literature, as well as individual oncologist opinions, all structured to provide patients with cancer outcome charts for various treatments from "people like me." Patients can use these comparisons to guide evidence-informed, shared decision making, with individual guidance from certified navigators.
What features differentiate your products from other similar offerings?
Robert (Bobby) Palmer, MBA: The most important distinction is point of intervention. Every other oncology support platform operates after the treatment decision has already been made. Navigation programs, second-opinion services, care-management tools, and payer-utilization programs all see the patient after the treatment plan is set. By then, cost and care trajectory are mostly locked in. PotentiaMetrics operates before all of them, at the moment the decision forms. That is the only moment at which the trajectory can be meaningfully redirected.
Capire360, our survival analytics engine, is built on more than 2.2 million real-world cancer cases from 500 or more institutions, covering 15 solid tumor types representing approximately 90% of adult cancer diagnoses, with longitudinal follow-up of up to 20 years. The models are Cox proportional-hazards survival models: transparent, auditable, and clinically interpretable—not a black-box output. They were externally validated at Erasmus University Medical Center, one of the foremost centers in clinical prediction modeling. Comorbidity burden is measured using the ACE-27, a validated scoring instrument, producing survival estimates that reflect the actual patient in the room, rather than a patient in the context of a clinical trial. The output is a set of individualized survival curves across realistic treatment alternatives at the modality level. Not population averages; a comparison with “people like me.” Learn more at potentiametrics.com.
The second distinction is independence. Ardynn, our PSDM platform, is delivered exclusively through certified patient advocates independent of any hospital, cancer center, or treating team. While hospital navigation programs facilitate delivery of a care pathway, Ardynn advocates support a patient's independent engagement in selecting a care pathway. A tool that routinely shows patients that less-aggressive treatment produces equivalent survival cannot maintain credibility if it originates inside an institution whose revenue depends on treatment delivery.
The third distinction is how the data is delivered. Ardynn advocates present survival information in absolute terms and natural frequencies rather than relative risks, because relative risk reductions cause patients to systematically overestimate treatment benefits. For any given patient, our PSDM approach begins with clinical practice guidelines from the National Comprehensive Cancer Network (NCCN), layers in Capire360 outcomes data stratified to that patient's profile, elicits and documents the patient's goals and quality of life priorities, and synthesizes all three into a PSDM Report shared with the clinical team before treatment discussions begin. The oncologist receives a patient who arrives prepared, with their questions organized and their values on record.
Curious Dr. George: How well is this approach working in 2026?
Robert (Bobby) Palmer, MBA: The outcomes are documented and consistent. Across an observational cohort of 76 patients and 11 cancer types, first-course treatment costs fell 40% following a full PSDM engagement, from $6.82 million in recommended treatment costs to $4.07 million for treatments actually received, with no clinically meaningful difference in five-year survival for any cancer type in the cohort. Average savings per patient were $34,000, a 15-to-1 return on investment to payers. Approximately 40% of patients chose less-aggressive treatment than originally recommended. This is not a lower standard of care. It is what consistently happens when patients have accurate personalized survival data and a structured opportunity to articulate what they value.
Patient experience mirrors the clinical outcomes. Our Net Promoter Score is +85, against a healthcare industry average of +40. More than 100 randomized trials confirm this pattern at scale: decision aids consistently increase values-concordant choices and reduce decisional conflict without increasing patient anxiety. One patient described the experience plainly: "Fear wanted to make the decision for me. Ardynn gave me my numbers, and for the first time, the choice actually felt like mine."
Curious Dr. George: How may patients with cancer, their caregivers, physicians, and health systems best access and use your services?
Robert (Bobby) Palmer, MBA: PotentiaMetrics operates under a live, auto-renewing contract with Surest, a UnitedHealthcare (UHC) health plan, and a master service agreement with UnitedHealthcare, representing full legal, compliance, clinical, actuarial, and data security review by the largest health insurer in the United States.
For patients and caregivers: If your employer offers UnitedHealthcare or UHC Surest benefits, ask your benefits administrator whether Ardynn is available to you. If you are outside those networks, contact us directly via rpalmer@potentiametrics.com. We navigate access on a case-by-case basis and will not turn away a patient who needs this.
For oncologists and clinical teams: Ardynn does not compete with the treating physician. It prepares the patient to meet with the physician as a genuine partner. The one-page pre-visit PSDM Report can be read in under two minutes, attaches to the chart, and supports MIPS quality measure documentation. Conservative modeling suggests the prepared-patient visit recovers approximately 10 minutes per new patient encounter. No EHR integration and no IT infrastructure is required to begin.
For health systems and payers operating in value-based contracts: Ardynn operates at the only moment in the cancer-care episode where cost and trajectory can actually be redirected, before the treatments have been decided on. Every downstream program is cheaper to run when the treatment decision that precedes it was made well.
Robert (Bobby) Palmer can be reached at rpalmer@potentiametrics.com.
.jpg)
.jpg)
